237748-26-4Relevant academic research and scientific papers
BTK Inhibitors and uses thereof
-
Paragraph 0933-0938, (2020/05/02)
The invention discloses a bruton's tyrosine kinase (BTK) inhibitor and use thereof. Specifically, the invention provides heteroaromatic compounds or stereoisomers, geometrical isomers, tautomers, racemates, nitrogen oxides, hydrates, solvates, metabolites and pharmaceutically acceptable salts or prodrugs thereof, and pharmaceutical compositions containing the heteroaromatic compounds; the invention also discloses use of the heteroaromatic compounds or the pharmaceutical compositions containing the heteroaromatic compounds in preparation of medicines; the medicines can be used for treating autoimmune diseases, inflammatory diseases or proliferative diseases.
1,4-Substituted Triazoles as Nonsteroidal Anti-Androgens for Prostate Cancer Treatment
Ferroni, Claudia,Pepe, Antonella,Kim, Yeong Sang,Lee, Sunmin,Guerrini, Andrea,Parenti, Marco Daniele,Tesei, Anna,Zamagni, Alice,Cortesi, Michela,Zaffaroni, Nadia,De Cesare, Michelandrea,Beretta, Giovanni Luca,Trepel, Jane B.,Malhotra, Sanjay V.,Varchi, Greta
supporting information, p. 3082 - 3093 (2017/04/21)
Prostate cancer (PC) is the fifth leading cause of cancer death in men, and the androgen receptor (AR) represents the primary target for PC treatment, even though the disease frequently progresses toward androgen-independent forms. Most of the commerciall
Concise synthesis of 6-cyanobenzo[ b ]furan, a useful building block
Nguyen, Son T.,Williams, John D.,Majgier-Baranowska, Helena,Li, Bing,Neelagiri, Venugopal R.,Kim, Hwa-Ok,Peet, Norton P.
, p. 1307 - 1313 (2014/04/17)
A new three-step synthesis of 6-cyanobenzo[b]furan (6) was developed, starting from commercially available 6-hydroxybenzo[b]furan-3-one (18). Key steps in this process were the first step, which was the reductive dehydration of 18 to produce 6-hydroxybenzo[b]furan (19), and the last step, which converted the aryl triflate 20 to the aryl cyanide 6 in a palladium-catalyzed cross-coupling protocol. Overall yield for this new synthesis was 49%.
DNA binding compounds. VII synthesis, characterization and DNA binding capacity of 1,2-dicarba-closo-dodecaborane bibenzimidazoles related to the DNA minor groove binder Hoechst 33258
Bateman, Stuart A.,Kelly, David P.,Martin, Roger F.,White, Jonathan M.
, p. 291 - 301 (2007/10/03)
A series of bibenzimidazole derivatives based on the known DNA minor groove binder Hoechst 33258 have been prepared to include a 1,2-dicarba-closo-dodecaborane cage for potential use in boron neutron capture therapy (BNCT). The carborane derivatives (5)-(7) were chosen to reduce the steric inhibition of minor groove DNA binding displayed by the previously prepared carborane ligand (4). The synthesis and preliminary DNA binding studies of these bibenzimidazole derivatives are presented herein.
3-[1,2-dicarba-closo-dodecacarboranyl-(methyleneoxy)]benzonitrile
White, Jonathan M.,Bateman, Stuart A.,Kelly, David P.,Martin, Roger F.
, p. 2785 - 2787 (2007/10/03)
The title compound, C10H17B10NO, contains a closo carbonane cage linked via a methyleneoxy tether to a substituted benzene ring. The carborane cage is essentially a regular dodecahedron with slight distortions owing to the
